Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Large numbers of blank-cheque groups are seeking deals, but the bloom might be coming off the rose.
Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.